相似文献
1
A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group.
Leukemia. 2016 Oct;30(10):2077-2080. doi: 10.1038/leu.2016.119. Epub 2016 May 2.
2
[Characteristic analysis of acute leukemia immunophenotyping in 180 cases by flow cytometry].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Feb;12(1):83-5.
3
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.
Haematologica. 2017 Dec;102(12):2058-2068. doi: 10.3324/haematol.2017.169029. Epub 2017 Sep 7.
4
[Acute myeloid leukemia with t(8;21): unusual cytological presentation and immunophenotype].
Ann Biol Clin (Paris). 2014 Jan-Feb;72(1):120-3. doi: 10.1684/abc.2013.0922.
5
[Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1405-9.
6
[Cytology and immunophenotype feautures of 80 acute myeloid leukemia].
Tunis Med. 2007 May;85(5):393-7.
7
Immunophenotypic patterns of childhood acute leukemias in Indonesia.
Asian Pac J Cancer Prev. 2011;12(12):3381-7.
8
[The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Zhonghua Xue Ye Xue Za Zhi. 2013 Feb;34(2):98-103.
9
Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia.
Ann Hematol. 2012 Oct;91(10):1541-6. doi: 10.1007/s00277-012-1501-7. Epub 2012 Jun 6.
10
Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
APMIS. 2010 May;118(5):353-9. doi: 10.1111/j.1600-0463.2010.02603.x.
引用本文的文献
1
Extramedullary Relapse of -Positive Megakaryoblastic Leukemia Mimicking Secondary Ewing Sarcoma: An Exemplary Case for the Diagnostic Trap.
Int J Mol Sci. 2025 Jun 19;26(12):5895. doi: 10.3390/ijms26125895.
2
Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia.
Res Sq. 2025 May 13:rs.3.rs-6528748. doi: 10.21203/rs.3.rs-6528748/v1.
3
Disease characteristics and outcomes of Croatian pediatric patients with acute lymphoblastic leukemia: pretreatment immunophenotypic predictors of high bone marrow minimal residual disease on day 15 of treatment.
Croat Med J. 2025 May 7;66(2):100-114. doi: 10.3325/cmj.2025.66.100.
4
Acute myeloid leukemia with RAM immunophenotype: A report of three patients and comprehensive literature review.
EJHaem. 2025 Feb 12;6(1):e1074. doi: 10.1002/jha2.1074. eCollection 2025 Feb.
5
Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56-positive acute leukemias.
EJHaem. 2024 Dec 16;6(1):e1052. doi: 10.1002/jha2.1052. eCollection 2025 Feb.
6
Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements.
Blood. 2025 May 29;145(22):2574-2586. doi: 10.1182/blood.2024026598.
7
Novel classification system and high-risk categories of pediatric acute myeloid leukemia.
Haematologica. 2025 Sep 1;110(9):1962-1973. doi: 10.3324/haematol.2024.285644. Epub 2025 Jan 9.
8
Rare Hematologic Malignancies and Pre-Leukemic Entities in Children and Adolescents Young Adults.
Cancers (Basel). 2024 Feb 29;16(5):997. doi: 10.3390/cancers16050997.
9
Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.
Ann Hematol. 2024 Apr;103(4):1103-1119. doi: 10.1007/s00277-024-05680-5. Epub 2024 Mar 6.
10
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group.
Haematologica. 2024 Oct 1;109(10):3182-3193. doi: 10.3324/haematol.2023.283757.
本文引用的文献
1
Pediatric acute myeloid leukemia: biology and therapeutic implications of genomic variants.
Pediatr Clin North Am. 2015 Feb;62(1):75-93. doi: 10.1016/j.pcl.2014.09.007. Epub 2014 Oct 29.
2
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
J Clin Oncol. 2014 Sep 20;32(27):3021-32. doi: 10.1200/JCO.2014.55.3628.
3
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.
Br J Haematol. 2014 Jul;166(2):254-259. doi: 10.1111/bjh.12852. Epub 2014 Mar 25.
4
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Ann Hematol. 2014 Jun;93(6):957-63. doi: 10.1007/s00277-014-2013-4. Epub 2014 Jan 19.
5
Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 2013 Dec;60(12):2073-8. doi: 10.1002/pbc.24573. Epub 2013 Aug 30.
6
Hematopoietic cell transplantation in high-risk childhood acute myelogenous leukemia.
Biol Blood Marrow Transplant. 2013 Jul;19(7):1002-3. doi: 10.1016/j.bbmt.2013.05.009.
7
The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia.
Rev Bras Hematol Hemoter. 2011;33(3):202-6. doi: 10.5581/1516-8484.20110054.
8
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.
Blood. 2012 Aug 23;120(8):1581-8. doi: 10.1182/blood-2012-02-408336. Epub 2012 May 30.
9
Biology, risk stratification, and therapy of pediatric acute leukemias: an update.
J Clin Oncol. 2011 Feb 10;29(5):551-65. doi: 10.1200/JCO.2010.30.7405. Epub 2011 Jan 10.
10
Clinical implications of FLT3 mutations in pediatric AML.
Blood. 2006 Dec 1;108(12):3654-61. doi: 10.1182/blood-2006-03-009233. Epub 2006 Aug 15.
Zotero 插件